Chelating Agents

Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS.

Also Known As:

Chelators; Metal Chelating Agents; Agent, Chelating; Agents, Chelating; Agents, Metal Chelating; Antagonists, Metal; Chelating Agents, Metal; Chelating Agent; Chelator; Complexons; Metal Antagonists

Networked: 4090 relevant articles (332 outcomes, 552 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Molecular Mechanisms of Pharmacological Action: 24
    - Sequestering Agents: 35
      - Chelating Agents: 4090
        Iron Chelating Agents: 130
        Calcium Chelating Agents: 114
- Specialty Uses of Chemicals
  - Sequestering Agents: 35
    - Chelating Agents: 4090
      - Iron Chelating Agents: 130
      - Calcium Chelating Agents: 114

Experts

1.	Richardson, Des R: 64 articles (09/2020 - 01/2002)
2.	Youdim, Moussa B H: 34 articles (01/2022 - 03/2004)
3.	Kalinowski, Danuta S: 31 articles (04/2019 - 12/2005)
4.	Hider, Robert C: 26 articles (12/2020 - 01/2002)
5.	Galanello, Renzo: 18 articles (10/2016 - 06/2003)
6.	Amit, Tamar: 18 articles (02/2016 - 09/2004)
7.	Fucharoen, Suthat: 17 articles (10/2020 - 03/2009)
8.	Kovacevic, Zaklina: 17 articles (01/2019 - 12/2006)
9.	Tolmachev, Vladimir: 16 articles (03/2020 - 11/2006)
10.	Richardson, D R: 16 articles (03/2013 - 01/2000)

Related Diseases

1.	Iron Overload 01/01/2015 - "Recent advances in imaging techniques and chelators development remarkably improved cardiac iron overload detection and treatment, respectively. " 10/01/2004 - "Early introduction of the chelating agent to combat iron overload in vulnerable organs leads to improved life expectancy. " 02/01/2012 - "Management of transfusional iron overload in SCA has been reported as suboptimal [1], but studies characterizing monitoring and treatment practices for iron overload in children with SCA, particularly in recent years with the expansion of chelator options, are lacking. " 01/01/2004 - "Clinical trials of the antitumor activity of chelators have been largely limited to DFO, which has been extensively studied as a consequence of its approved use for treatment of secondary iron overload. " 08/01/1995 - "This study presents new data favoring the potential clinical interest of this new class of chelating agents in the treatment of human iron overload."
2.	Neoplasms (Cancer) 03/10/2013 - "These changes can be therapeutically manipulated by the use of novel chelators that have recently been shown to be highly effective in terms of inhibiting tumor growth. " 08/01/2012 - "These findings suggest that strong Zn-chelating agents may be useful in the treatment of apoptosis-resistant human cancers." 05/01/2007 - "Redox-inactive Fe chelator complexes are well suited for the treatment of Fe-overload diseases, whereas Fe chelator complexes with high redox activity have shown promising results as chemotherapeutics against cancer. " 10/03/2006 - "The aim of this study was to evaluate the antitumor activity and Fe chelation efficacy of a new class of Fe chelators using human tumors. " 10/04/2010 - "The influence of the chelator on biodistribution properties was less than that of glycation, which clearly improved the tumor-to-background ratios."
3.	Thalassemia 05/01/1992 - "[New therapeutic trends in thalassemia: oral chelating agents]." 01/01/2023 - "A Multicenter ICET-A Study on Age at Menarche and Menstrual Cycles in Patients with Transfusion-Dependent Thalassemia (TDT) who Started Early Chelation Therapy with Different Chelating Agents." 01/01/2023 - "To evaluate the effect of early chelation therapy (≤ 3 years) with a variety of chelating agents on age at menarche and menstrual characteristics in patients with transfusion-dependent thalassemia (TDT). " 10/01/2014 - "We examine stability of health-related quality of life (HRQOL) in thalassemia and adherence to chelation therapy over time, especially after changes in chelator choice. " 01/01/1990 - "Design, properties, and effective use of the oral chelator L1 and other alpha-ketohydroxypyridines in the treatment of transfusional iron overload in thalassemia."
4.	Hepatolenticular Degeneration (Wilson's Disease) 03/23/1958 - "[Pure hepatic form of Wilson's disease in infant; successful therapy with chelating agents]." 06/01/1990 - "We conclude that long-term Zn treatment in Wilson's disease can be a safe and effective alternative to Cu chelating agents. " 10/01/2021 - "Finally, we cover the use of established and novel chelating agents, paradoxical neurological worsening, and progress developing targeted molecular and gene therapy for Wilson's disease, before discussing future directions for translational research." 01/01/2020 - "A liver-targeting Cu(i) chelator relocates Cu in hepatocytes and promotes Cu excretion in a murine model of Wilson's disease." 01/01/2019 - "In Wilson disease combination of a hydrophilic chelator e.g. "
5.	Infections 01/09/2023 - "Radiometal chelators for infection diagnostics." 04/13/2021 - "In contrast to few moderate changes induced by single treatments (either infection or chelator), most genes had highest upregulation in the infected groups receiving DFO. " 10/20/2018 - "We focused our interest on the design of chelators to address Mycobacterium avium infections. " 02/01/2014 - "Interestingly, ∆RD1 infection did not increase intracellular Ca(2+) levels, and Ca(2+) chelators markedly inhibited IL-1α secretion in response to H37Rv infection. " 05/01/2008 - "Each was radiolabeled with (99m)Tc using the chelator MAG(3), and were evaluated for binding to host and non-host bacteria in vitro and in a mouse infection model. "

Related Drugs and Biologics

1.	Iron
2.	Deferoxamine (Desferal)
3.	Deferasirox
4.	Deferiprone
5.	Copper
6.	Antioxidants
7.	Metals
8.	Zinc
9.	Edetic Acid (EDTA)
10.	tetrathiomolybdate (ammonium tetrathiomolybdate)

Related Therapies and Procedures

1.	Therapeutics
2.	Chelation Therapy (Therapy, Chelation)
3.	Blood Transfusion (Blood Transfusions)
4.	Radioimmunotherapy
5.	Aftercare (After-Treatment)